Company Profile
MicroPort Endovastec, formerly Lombard Medical, part of MicroPort Corporation, is dedicated to advancing endovascular treatment of aortic disease. Our portfolio includes unique TEVAR, FEVAR, and EVAR solutions, empowering physicians with innovative technologies that improve patient outcomes and broaden therapeutic possibilities worldwide.
To find out more, please contact our Clinical Specialist Sales Team.
Highlights From Our History
1994
Lombard Medical is founded
1998
The birth of AorfixTM EVAR stent graft
2001
AorfixTM is CE marked
2004
AorfixTM is CE marked for 0-65° angulated necks
2007
AorfixTM US Pythagoras clinical trial begins
2009
AorfixTM is CE marked for 0-90° angulated necks
2012
AorflexTM
Generation Three delivery system introduced
2013
AorfixTM approved by FDA
2014
AorfixTM approved
in Japan
2016
IntelliflexTM Generation Four delivery system introduced
2016
Acquisition of
AlturaTM EVAR
stent graft
2018
Partnership with MicroPort Endovastec
May 2020
European launch of HerculesTM TEVAR stent graft
May 2020
European launch of MinosTM EVAR
stent graft
Oct 2020
First Fenestrated AlturaTM FEVAR stent graft
Feb 2021
European launch of CastorTM branched
TEVAR stent graft
April 2023
Fenestrated AlturaTM marketed as MeridianTM FEVAR
stent graft
August 2024
Lombard Medical acquired by MicroPort Endovastec
April 2025
European launch of CratosTM TEVAR stent graft
Sept 2025
European launch of HectorTM TEVAR stent graft
April 2026
Lombard Medical commercially rebrands as MicroPort Endovastec
